Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Cancer Immunol Res. 2021 Jul;9(7):765-778. doi: 10.1158/2326-6066.CIR-20-0499. Epub 2021 Apr 10.
The mechanisms behind the antitumor effects of exercise training (ExTr) are not fully understood. Using mouse models of established breast cancer, we examined here the causal role of CD8 T cells in the benefit acquired from ExTr in tumor control, as well as the ability of ExTr to improve immunotherapy responses. We implanted E0771, EMT6, MMTV-PyMT, and MCa-M3C breast cancer cells orthotopically in wild-type or female mice and initiated intensity-controlled ExTr sessions when tumors reached approximately 100 mm We characterized the tumor microenvironment (TME) using flow cytometry, transcriptome analysis, proteome array, ELISA, and immunohistochemistry. We used antibodies against CD8 T cells for cell depletion. Treatment with immune checkpoint blockade (ICB) consisted of anti-PD-1 alone or in combination with anti-CTLA-4. ExTr delayed tumor growth and induced vessel normalization, demonstrated by increased pericyte coverage and perfusion and by decreased hypoxia. ExTr boosted CD8 T-cell infiltration, with enhanced effector function. CD8 T-cell depletion prevented the antitumor effect of ExTr. The recruitment of CD8 T cells and the antitumor effects of ExTr were abrogated in mice, supporting the causal role of the CXCL9/CXCL11-CXCR3 pathway. ExTr also sensitized ICB-refractory breast cancers to treatment. Our results indicate that ExTr can normalize the tumor vasculature, reprogram the immune TME, and enhance the antitumor activity mediated by CD8 T cells via CXCR3, boosting ICB responses. Our findings and mechanistic insights provide a rationale for the clinical translation of ExTr to improve immunotherapy of breast cancer.
运动训练(ExTr)抗肿瘤作用的机制尚不完全清楚。在这里,我们使用已建立的乳腺癌小鼠模型,研究了 CD8 T 细胞在 ExTr 控制肿瘤获益中的因果作用,以及 ExTr 改善免疫治疗反应的能力。我们将 E0771、EMT6、MMTV-PyMT 和 MCa-M3C 乳腺癌细胞原位植入野生型或 雌性小鼠中,并在肿瘤达到约 100 mm 时开始进行强度控制的 ExTr 疗程。我们使用流式细胞术、转录组分析、蛋白质组阵列、ELISA 和免疫组织化学来表征肿瘤微环境(TME)。我们使用针对 CD8 T 细胞的抗体进行细胞耗竭。免疫检查点阻断(ICB)治疗包括单独使用抗 PD-1 或与抗 CTLA-4 联合使用。ExTr 延迟了肿瘤生长并诱导血管正常化,表现为周细胞覆盖和灌注增加,缺氧减少。ExTr 增强了 CD8 T 细胞的浸润,并增强了其效应功能。CD8 T 细胞耗竭可阻止 ExTr 的抗肿瘤作用。在 小鼠中,CD8 T 细胞的募集和 ExTr 的抗肿瘤作用被阻断,支持了 CXCL9/CXCL11-CXCR3 途径的因果作用。ExTr 还使 ICB 难治性乳腺癌对治疗敏感。我们的结果表明,ExTr 可以使肿瘤血管正常化,重新编程免疫 TME,并通过 CXCR3 增强 CD8 T 细胞介导的抗肿瘤活性,从而增强 ICB 反应。我们的发现和机制见解为将 ExTr 临床转化以改善乳腺癌的免疫治疗提供了依据。